


# The ProTetanus Experience - ticks all the boxes



By engaging with the **ProTetanus Experience**, we hope to provide you with comprehensive background information and a demonstration of this immunochromatographic assay that will inform your decision to integrate **ProTetanus** into your wound management protocol.


Assessment of Anti-Tetanus Antibody status is dependent on 5 key considerations:

-  **1** 100% SPECIFICITY  
No False Positive results
-  **2** A Value Proposition
-  **3** Improved Clinical Management of Tetanus-Prone Wounds
-  **4** Quality Assessment
-  **5** After Sales Care & Support




## Result

**T**   **C**



+ve for anti-tetanus antibodies

**T**   **C**



-ve

Point-of-care, single-step immunoassay test  
Clear, easy to read results within 10 minutes.

Requires only 20µl of whole blood, serum or plasma.

**prospect**  
Diagnostics Limited

*improving clinical outcomes*

# In the context of Anti-Tetanus Prophylaxis, what are the needs of your organisation?

## 1 100% SPECIFICITY

Several peer-reviewed clinical studies<sup>1</sup> confirm the high sensitivity (96.4%) and high specificity (100%) of the ProTetanus assay. The most important benefit of these characteristics is that it is impossible to have a false-positive assay.

## 3 Improved Clinical Management of Tetanus-Prone Wounds

ProTetanus enables clinicians to make an informed decision as to whether or not anti-tetanus prophylaxis is indicated.

A positive ProTetanus result indicates levels of anti-tetanus antibodies that are at least 10 times the threshold set out by the WHO as providing adequate sero-protection against Tetanus.

The clinician can have complete confidence in the clinical pathway and at the same time avoid issues of overimmunisation and potential allergic reactions.

## 4 Quality Assessment

The ProTetanus control set contains vials of positive and negative control sera for periodic confirmation of the functionality of ProTetanus platforms. These control sera are presented to the assay platform in exactly the same way as a patient's sample.

## 2 A Value Proposition

Patients presenting with a tetanus-prone wound are frequently unaware of their anti-tetanus immune status and are rarely able to provide supportive evidence. With the imperative that no patients should leave the department exposed to a risk of infection, anti-tetanus prophylaxis using tetanus toxoid triple vaccine or immunoglobulin is often prescribed.

In the absence of a definitive measure of anti-tetanus immunity status, this guideline is expensive and at best, a clinical compromise.

In a study of the impact of ProTetanus, a point-of-care assay for anti-tetanus antibodies, Jane McVicar et al<sup>2</sup> concluded that 39% of the cohort of tetanus-prone wound patients would have received unnecessary prophylaxis. Clearly, the adoption of ProTetanus ensures clinical best practice and delivers significant cost savings.

	TTB	HTIG	ProTetanus Kit
Cost per patient	£7.80	£250.00	£4.88

## 5 After Sales Care & Support

- Support line Monday-Friday (9am - 5pm)
- Regular updates
- Standard next day delivery (99%)
- Standing orders for supplies

Having completed the ProTetanus Experience, we invite you to review your five considerations

Now tick your boxes! ✓

- 1  100% SPECIFICITY  
No False Positive results
- 2  A Value Proposition
- 3  Improved Clinical Management of Tetanus-Prone Wounds
- 4  Quality Assessment
- 5  After Sales Care & Support

"Taking everything into account, ProTetanus provides a compelling and effective Point-of-Care solution to managing Tetanus-prone wounds."

### Selected bibliography

1. D. Elkharrat et al.  
Médecine et maladies infectieuses  
35 (2005) 323-328  
Incorporation of a rapid test into the current French Ministry of Health National Framework in order to optimise the antitetanus prophylaxis offered in wound management by accident & emergency departments.

2. J. McVicar et al.  
Emerg Med J 2013;30:177-179  
Should we test for tetanus immunity in all emergency department patients with wounds?

**prospect**  
Diagnostics Limited

improving clinical outcomes